{
    "nctId": "NCT01069211",
    "briefTitle": "Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women",
    "officialTitle": "Assessment of Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 876,
    "primaryOutcomeMeasure": "Disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with estrogen receptor(+) and/or progesterone receptor(+)\n2. Postmenopausal state was defined the following conditions, at least one of a, b\n\n   1. Serum FSH \u2265 30 mIU/mL and Amenorrhea \u2265 1 year for below 55 years, over than 55 years\n   2. Bilateral oophorectomy\n3. Patients have undergone surgery of the breast cancer within 12 weeks and terminated chemotherapy after surgery within 4 weeks.\n4. WHO(ECOG) performance status 0-2\n5. Adequate haematological function, renal function, hepatic function.\n6. No evidence of metastasis.\n\nExclusion Criteria:\n\n1. Metachronous bilateral breast cancer.\n2. Metastatic breast cancer (stage IV)\n3. Other hormone therapy and Hormonal replacement therapy given within the previous 4 weeks, except for Estring, Vagifem, Estrogen Cream.\n4. Patients with Child-Pugh grade C, serum creatinine\\>2xUNL\n5. Patients with gastrectomy, small bowel resection, malabsorption syndrome and dysphagia.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}